Lung cancer drug osimertinib under microscope: biopsies reveal resistance secrets

NCT ID NCT03586453

Ongoing Disease control Sponsor: Dana-Farber Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests the targeted therapy osimertinib (Tagrisso) in 30 people with advanced non-small cell lung cancer that has a specific EGFR mutation. Participants take osimertinib daily and undergo tumor biopsies during treatment and after the cancer progresses. The main goal is to understand how the cancer becomes resistant to the drug, which could guide future treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Osimertinib (Tagrisso)
What this could lead to: If successful, this could help doctors understand why some lung cancers stop responding to osimertinib, potentially leading to better treatment strategies.
What could go wrong: This is a small, early-phase study focused on understanding resistance, not proving a cure. Results may not apply to all patients, and biopsies carry risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARCINOMA, NON-SMALL-CELL LUNG

Contacts and locations

Locations

Beth Israel Deaconess Medical Center

Boston, Massachusetts, 02215, United States
Dana-Farber Cancer Institute

Boston, Massachusetts, 02215, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.